Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

This study highlights that hydrogel formulations unexpectedly prolonged healing in trials, pointing to a need for design based on detailed pathophysiological insights rather than empirical methods, and suggests technologies like AI materials optimization and 3D bioprinting to aid their clinical use for cancer survivors.

New microneedle method improves hair regrowth treatment delivery.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

This study found that a 4:1 combination of Rhynchosia nulubilis and Polygonum multiflorum extracts significantly promoted the proliferation of human dermal papilla cells and alleviated testosterone-induced cytotoxicity, suggesting potential for treating hair loss and related disorders through a synergistic approach.

Deuruxolitinib is generally safe for treating alopecia areata.

This study found that OZiva+ advanced hair growth serum significantly increased hair follicle length and showed no irritation, indicating it may be a safer alternative to traditional hair loss treatments like minoxidil.

This study describes a multifunctional hydrogel system designed to treat androgenetic alopecia by integrating nanozymes for reactive oxygen species clearance and melanin nano photothermal agents to enhance hair follicle health, suggesting potential for multi-target precision therapy and improved hair growth.

In this study, ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.

This article discusses the efficacy of different derma roller sizes compared to topical applications for administering QR678 Neo® in treating androgenetic alopecia, but provides no new clinical results.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

In this study, a new emulsion containing CBD and ginger root extract significantly reduced symptoms of dry and eczema-prone skin, such as erythema and itching, in a clinical trial.

This study reports various adverse effects associated with different doses and administration methods of a medical treatment, including gastrointestinal issues and hair loss, leading to modifications or discontinuations in some patients.

This article discusses female androgenetic alopecia but reports no new clinical findings.

This compilation lists potential side effects, drug interactions, and trade names of various dermatological and antiretroviral medications, but it reports no original research findings.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

This study found that local PGE2 injection may prevent radiotherapy-induced hair loss by protecting hair follicle cells and promoting hair follicle self-repair.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This case report describes a young female with Rhupus syndrome, characterized by symptoms of both Systemic Lupus Erythematosus and Rheumatoid Arthritis, who achieved clinical remission with treatment.

This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.

The document concludes that using gadolinium-based contrast agents during MRI can be linked to Nephrogenic Systemic Fibrosis in patients with severe kidney disease.

This study evaluated a new aqueous-based nanosuspension of minoxidil for treating androgenetic alopecia and reported it was as effective as the commercial product but had better safety and tolerability, potentially improving patient compliance.

The study found that Anagen grow, a herbal serum, promotes hair growth elongation and may inhibit the alpha reductase enzyme, suggesting it as a safe, effective alternative to finasteride and beneficial alongside minoxidil for reducing scalp dryness.

This study found that topical ruxolitinib protected Lgr5+ skin stem cells and maintained skin homeostasis in skin GVHD, unlike corticosteroids.